Impact of regulatory interventions to restrict the combined use of renin-angiotensin system-acting agents: A Danish nationwide drug utilisation study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 575 KB, PDF-dokument
This study aimed to evaluate the impact of the risk minimisation measures issued by the European Medicines Agency in 2014 to restrict the combined use of renin-angiotensin system (RAS) agents in Denmark. Data from the Danish National Prescription Registry covering all medications dispensed during January 2008-December 2018 was used. The outcome was monthly prevalence of patients co-dispensed RAS-acting agents. Autoregressive integrated moving average interrupted time series regression was used to evaluate dispensing trends. The prevalence of patients co-dispensed RAS-acting agents decreased from 0.01.0003intervention trend was declining and further decreased with an additional -0.45 (950.66, -0.25) co-dispensing per million population after the intervention. Overall, the intervention had minimal impact on the combined use of RAS-acting agents. However, as the combined use of RAS-acting agents is low, further interventions to restrict the combined use of RAS-acting agents may not be required in Denmark at this point.
Originalsprog | Engelsk |
---|---|
Tidsskrift | British Journal of Clinical Pharmacology |
Vol/bind | 88 |
Udgave nummer | 3 |
Sider (fra-til) | 1379-1384 |
ISSN | 1365-2125 |
DOI | |
Status | Udgivet - 2022 |
- ACE inhibitors, angiotensin II receptor blockers, drug safety, drug utilisation, pharmacovigilance, Renin angiotensin system, risk management
Forskningsområder
Antal downloads er baseret på statistik fra Google Scholar og www.ku.dk
Ingen data tilgængelig
ID: 279716358